{"name":"Shanghai Escugen Biotechnology Co., Ltd","slug":"shanghai-escugen-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ESG206","genericName":"ESG206","slug":"esg206","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ESG206","genericName":"ESG206","slug":"esg206","phase":"phase_2","mechanism":"ESG206 is a small molecule targeting the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQSGtiZUFmcUJwZDYxeFB4TElfdGhWbEZUZ0R5NFVWTER3VXN0LUxSMnpoeDI5eUdxOU9seUdzVHF5YlFVTjZydUN1LTk4bWJjeGRxOWZMcEZOS1BSOVUtTnBjR2JMMjM1MFZzZUttNHk2c2lfNnZ4UjFxQ2dPX3dTcDJaSlhYdzA4UUd6MjFDUTlpVVM0Z2lDVG9TRzhHdkg1YThRT2pLWHhWYzVUSGw4N0djTkZKTS1wd3BDTm9laEVpWFVCNGctUlo5Ni04NGRTcEF6UWZTanBYWTFMaFE?oc=5","date":"2025-06-17","type":"pipeline","source":"businesswire.com","summary":"SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC - businesswire.com","headline":"SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOVk1MeWpUX0h6ZmNMVThlSmtid0lpTGR0QmoyQXVuWDBvankzVVFlZWpJa2RORG55Z0k1YUlQRTR3WDRQa2RwOUh2OWFuby1PdGZWTEFmTlZHMGFyRjdTaFkzOTdRQXB5clVtT3V2MU9wVTl1UWRuTnRrenhQa0ktcWE3TDduSnkyOEhvWUp3bU01U0QyMXBqczF2cE5ta196RjNBa0VRWTdkMXdPSGYtc2pMcm9mM1NLV1UtMnJhNml2aC1XdElMcjBvYjV2QmpOaHlhU0FiNmQ5aTRIQ00teEx6OFZmM3FmT3R3Z01fRlQwNGtJbVEwbWxLOG1SMFgwTTJaLU93V2Y0LWYy?oc=5","date":"2025-01-29","type":"trial","source":"GlobeNewswire","summary":"Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire","headline":"Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNMFRpbk1ZWUdmZmpDSm1pQ1E3c0ppbEU0S05IbzdxV0U4V1loYTZ6Qk5iZk5HRHg4Tkp1TUxnR2dGSXRHTkhtbzFTM0lIRG5reWFrNE9KY2dnZmtyNlFwODQ4ZzF2eVk5cjJ4SktKWE9fYlpiV1FaQ2pnTzdfbElzTjJxQ1VHVmFUazlCTzIxcjAzSUY2eTFIcWVMQ0tBWTZrOG90eWdqaHhIX0FUdC1MS3JLWlpob3NWRnpJN19jRVdlUmVFR2QtVmo4S0Qxc1pYODAxRkNVYzFGY0R6OVhOOXpjaWxmU1k2cGlHWEZTeGozSHV5UjM4MHNLUTgzZ0c5ZlVjUTJMR1FvWlAtN2c?oc=5","date":"2024-07-11","type":"pipeline","source":"Ipsen","summary":"Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential - Ipsen","headline":"Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-06-05","type":"trial","source":"GlobeNewswire","summary":"Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patient","headline":"Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results f","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}